Total Funding
89
43
Total FundingVenture - Series Unknown raised
Growth Score
-2 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
30408
EvolveImmune Therapeutic develops cancer immunotherapy products focused on trispecific T cell engagers with integrated CD2 costimulation.
- Stephen Bloch: Co-Founder & Chief Executive OfficerPast Role: OmniSonics Medical Technologies, Team Member
Sidi Chen: Founder
About the Company
EvolveImmune Therapeutics builds therapies designed to improve immune system activation against cancer cells that resist existing immunotherapy approaches. Its EVOLVE platform supports a pipeline of drug candidates aimed at enhancing T cell engagement and immune response within oncology treatment settings. The lead internal candidate, EVOLVE104, is
positioned for clinical development, and the company also collaborates with external partners such as Abbvie to expand research and development of additional immune-based therapeutics.
